All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.
COVID-19 and EBMT recommendations for patients with hematological malignancies
A summary article on the latest guidelines and recommendations for the management of Coronavirus Disease 2019 (COVID-19) in patients with hematological malignancies.
What are the options for cell-based therapies in mantle cell lymphoma?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Mehdi Hamadani, Medical College of Wisconsin,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox